Artesunate
Identification
- Summary
Artesunate is artesunate is an artemesinin derivative indicated for the initial treatment of severe malaria.
- Generic Name
- Artesunate
- DrugBank Accession Number
- DB09274
- Background
Artesunate is indicated for the initial treatment of severe malaria.8 The World Health Organization recommends artesunate as first line treatment for severe malaria.6 Artesunate was developed out of a need for a more hydrophilic derivative of artemisinin.5
Artesunate was granted FDA approval on 26 May 2020.8
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
- Weight
- Average: 384.425
Monoisotopic: 384.178417862 - Chemical Formula
- C19H28O8
- Synonyms
- Artesunate
- Artesunato
- Artesunatum
- Artesunic acid
- AS
- butanedioic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] ester
- dihydroqinghasu hemsuccinate
- Succinyl dihydroartemisinin
- External IDs
- 182824-33-5
- NSC-712571
Pharmacology
- Indication
Artesunate is indicated for the initial treatment of severe malaria in adult and pediatric patients.8
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Acute uncomplicated plasmodium falciparum malaria Combination Product in combination with: Mefloquine (DB00358) •••••••••••• •••••• Treatment of Malaria, cerebral •••••••••••• •••••••••• ••••••• ••• •••••••• Treatment of Severe malaria •••••••••••• •••••• Treatment of Severe malaria •••••••••••• •••••• ••••••••• ••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Artesunate is an artemisinin derivative that is metabolized to DHA, which generates free radicals to inhibit normal function of Plasmodium parasites.1,7,8 It has a short duration of action due to its short half life, and a moderate therapeutic index.7,8 Patients should be counselled regarding the risk of post treatment hemolytic anemia and hypersenstivity.8
- Mechanism of action
Artesunate is metabolized to the active DHA.8 the endoperoxide bridge of DHA reacts with heme, generating free radicals which inhibit protein and nucleic acid synthesis of the Plasmodium parasites during all erythrocytic stages.8,7 Reactions with these free radicals can also lead to alkylation of parasitic proteins such as a calcium adenosine triphosphatase and EXP1, a glutathione S-transferase.1,7
Target Actions Organism AMalaria protein EXP-1 inhibitorPlasmodium falciparum - Absorption
The Cmax of artesunate is 3.3µg/mL while the Cmax of the active metabolite DHA is 3.1µg/mL.8 The AUC of artesunate is 0.7µg*h/mL while the AUC of DHA is 3.5µg*h/mL.8 After intravenous artesunate, DHA has a Tmax of 0.5-15 minutes in adult patients and 21-64 minutes in pediatric patients.7 Intramuscular artesunate has a Tmax of 8-12 minutes.7 Infants less than 6 months old will have a higher AUC due to an undeveloped UGT metabolic pathway.8
- Volume of distribution
The volume of distribution of artesunate is 68.5L while the volume of distribution of DHA is 59.7L.8
- Protein binding
Artesunate and its metabolite DHA are approximately 93% protein bound in plasma.8 Artesunate can bind to serum albumin.4
- Metabolism
Artesunate is rapidly metabolized to dihydroartemisinin (DHA) by plasma esterases.8 DHA is glucuronidated by UGT1A9 and UGT2B7 to DHA-glucuronide.2,8 DHA-glucuronide can undergo a minor metabolic pathway to for a furano acetate derivative of DHA-glucuronide.2 CYP2A6 may minorly contribute to the metabolism of artesunate.7
Hover over products below to view reaction partners
- Route of elimination
The main route of elimination in humans is unknown.8 In rats, a dose of artesunate is 56.1% eliminated in the urine and 38.5% in the feces.3
- Half-life
The elimination half life of artesunate is 0.3h with a range of 0.1-1.8h.8 The elimination half life of DHA is 1.3h with a range of 0.9-2.9h.8 Half life after intramuscular administration is 48 min in children and 41 min in adults.7
- Clearance
The clearance of artesunate is 180L/h while the clearance of DHA is 32.3L/h.8
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Data regarding overdoses of artesunate are rare.8 Patients experiencing an overdose may present with pancytopenia, melena, seizures, multiorgan failure, and death.8 Treat overdose with symptomatic and supportive measures.8
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetophenazine The risk or severity of QTc prolongation can be increased when Artesunate is combined with Acetophenazine. Alimemazine The risk or severity of QTc prolongation can be increased when Artesunate is combined with Alimemazine. Ambroxol The risk or severity of methemoglobinemia can be increased when Artesunate is combined with Ambroxol. Artemether The risk or severity of QTc prolongation can be increased when Artesunate is combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Artesunate is combined with Articaine. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Artesunate sodium CN5E49Z611 82864-68-4 ZISJLHQNEVGTIU-RFEYTNPVSA-M - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Artesunate Injection, powder, for solution; Kit 110 mg/1 Parenteral Amivas, Inc 2020-12-11 Not applicable US Artesunate - Amivas Injection, powder, for solution 110 mg Intravenous Amivas Ireland Ltd 2022-01-21 Not applicable EU Artesunate - Amivas Injection, powder, for solution 110 mg Intravenous Amivas Ireland Ltd 2022-01-21 Not applicable EU - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Artesunate Artesunate (110 mg/1) + Artesunate (110 mg/1) Injection; Kit Parenteral Amivas, LLC 2020-12-11 Not applicable US Artesunate Artesunate (110 mg/1) + Artesunate (110 mg/1) Injection; Kit Parenteral Amivas, LLC 2020-12-11 Not applicable US PYRAMAX TABLETS Artesunate (60 MG) + Pyronaridine tetraphosphate (180 MG) Tablet, film coated บริษัท ดีซีเอฟ เฮลท์แคร์ จำกัด 2017-10-10 Not applicable Thailand อาร์ทีซูเนทและเมฟลอควินไฮโดรคลอไรด์ 100/220 มก. Artesunate (100 MG) + Mefloquine hydrochloride (220 MG) Tablet, film coated บริษัท ฮีลลอล ฟาร์มาซูติคอล จำกัด จำกัด 2019-04-10 Not applicable Thailand อาร์ทีซูเนทและเมฟลอควินไฮโดรคลอไรด์ 25/55 มก. Artesunate (25 MG) + Mefloquine hydrochloride (55 MG) Tablet, film coated บริษัท ฮีลลอล ฟาร์มาซูติคอล จำกัด จำกัด 2019-04-10 Not applicable Thailand
Categories
- ATC Codes
- P01BE03 — Artesunate
- P01BE — Artemisinin and derivatives, plain
- P01B — ANTIMALARIALS
- P01 — ANTIPROTOZOALS
- P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
- P01BF — Artemisinin and derivatives, combinations
- P01B — ANTIMALARIALS
- P01 — ANTIPROTOZOALS
- P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
- P01BF — Artemisinin and derivatives, combinations
- P01B — ANTIMALARIALS
- P01 — ANTIPROTOZOALS
- P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
- P01BF — Artemisinin and derivatives, combinations
- P01B — ANTIMALARIALS
- P01 — ANTIPROTOZOALS
- P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
- P01BF — Artemisinin and derivatives, combinations
- P01B — ANTIMALARIALS
- P01 — ANTIPROTOZOALS
- P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
- Drug Categories
- Acids, Acyclic
- Anions
- Anthelmintics
- Anti-Infective Agents
- Antimalarials
- Antineoplastic Agents
- Antiparasitic Agents
- Antiparasitic Products, Insecticides and Repellents
- Antiplatyhelmintic Agents
- Antiprotozoals
- Antiviral Agents
- Artemisinin and derivatives
- Artemisinins
- BCRP/ABCG2 Substrates
- Cytochrome P-450 CYP2A6 Substrates
- Cytochrome P-450 Substrates
- Dicarboxylic Acids
- Electrolytes
- Free Radicals
- Ions
- OAT3/SLC22A8 Inhibitors
- OATP1B1/SLCO1B1 Inhibitors
- Oxides
- Oxygen Compounds
- P-glycoprotein substrates
- Peroxides
- Reactive Oxygen Species
- Schistosomicides
- Terpenes
- UGT1A9 Substrates
- UGT2B7 substrates
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as artemisinins. These are sesquiterpenoids originally isolated from the herb Artemisia annua. Their structure is based on artemisinin, a tetracyclic compound that contains a 1,2-dioxepane fused to an octahydrobenzopyran moiety. The internal peroxide bridge is believed to be a key to the mode of action of artemisinins.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Sesquiterpenoids
- Direct Parent
- Artemisinins
- Alternative Parents
- Oxepanes / Heterocyclic fatty acids / Fatty acid esters / Trioxanes / Oxanes / Dicarboxylic acids and derivatives / Dialkyl peroxides / Carboxylic acid esters / Oxacyclic compounds / Carboxylic acids show 3 more
- Substituents
- 1,2,4-trioxane / Acetal / Aliphatic heteropolycyclic compound / Artemisinin skeleton / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid ester / Dialkyl peroxide / Dicarboxylic acid or derivatives show 11 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- dicarboxylic acid monoester, semisynthetic derivative, sesquiterpenoid, artemisinin derivative, cyclic acetal (CHEBI:63918)
- Affected organisms
- Plasmodium
Chemical Identifiers
- UNII
- 60W3249T9M
- CAS number
- 88495-63-0
- InChI Key
- FIHJKUPKCHIPAT-AHIGJZGOSA-N
- InChI
- InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1
- IUPAC Name
- 4-oxo-4-{[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0⁴,¹³.0⁸,¹³]hexadecan-10-yl]oxy}butanoic acid
- SMILES
- [H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4
References
- General References
- Lisewski AM, Quiros JP, Ng CL, Adikesavan AK, Miura K, Putluri N, Eastman RT, Scanfeld D, Regenbogen SJ, Altenhofen L, Llinas M, Sreekumar A, Long C, Fidock DA, Lichtarge O: Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate. Cell. 2014 Aug 14;158(4):916-28. doi: 10.1016/j.cell.2014.07.011. [Article]
- Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, Thu le TA, Hung NC, Pirmohamed M, Park BK, Edwards G: Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos. 2002 Sep;30(9):1005-12. doi: 10.1124/dmd.30.9.1005. [Article]
- Li Q, Xie LH, Haeberle A, Zhang J, Weina P: The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans. Am J Trop Med Hyg. 2006 Nov;75(5):817-26. [Article]
- Veerappan A, Eichhorn T, Zeino M, Efferth T, Schneider D: Differential interactions of the broad spectrum drugs artemisinin, dihydroartemisinin and artesunate with serum albumin. Phytomedicine. 2013 Aug 15;20(11):969-74. doi: 10.1016/j.phymed.2013.04.003. Epub 2013 May 16. [Article]
- White NJ, Hien TT, Nosten FH: A Brief History of Qinghaosu. Trends Parasitol. 2015 Dec;31(12):607-610. doi: 10.1016/j.pt.2015.10.010. [Article]
- CDC: Artesunate [Link]
- Artesunate Product Information [Link]
- FDA Approved Drug Products: Artesunate Intravenous Injection [Link]
- External Links
- Human Metabolome Database
- HMDB0240267
- KEGG Drug
- D02482
- PubChem Compound
- 6917864
- PubChem Substance
- 310265169
- ChemSpider
- 5293084
- 18346
- ChEBI
- 63918
- ChEMBL
- CHEMBL361497
- ZINC
- ZINC000014096305
- PDBe Ligand
- D95
- Wikipedia
- Artesunate
- PDB Entries
- 6fgc / 6yk1
- FDA label
- Download (360 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Malaria / Parasitic Diseases 1 4 Active Not Recruiting Treatment Malaria 2 4 Active Not Recruiting Treatment Uncomplicated Malaria caused by Plasmodium falciparum 1 4 Completed Not Available Healthy Subjects (HS) 1 4 Completed Health Services Research Malaria 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intravenous 60 mg Injection, powder, for solution; kit Parenteral 110 mg/1 Injection; kit Parenteral Injection, powder, for solution Intravenous 110 mg Powder 60 mg/1vial Tablet 50 mg Tablet, film coated Oral 50 mg Tablet, film coated Oral 200 mg Capsule, liquid filled Rectal 200 mg Tablet, film coated - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 131-135 MSDS - Predicted Properties
Property Value Source Water Solubility 0.678 mg/mL ALOGPS logP 2.35 ALOGPS logP 3.1 Chemaxon logS -2.8 ALOGPS pKa (Strongest Acidic) 3.77 Chemaxon pKa (Strongest Basic) -4.2 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 100.52 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 89.95 m3·mol-1 Chemaxon Polarizability 39.46 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0096000000-2a4fa36d13ab900a06f4 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-1091000000-9fdcf05d1d9031635640 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00kr-1094000000-e7218ed1e326d4796ed5 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00e9-9021000000-151b8724a431ab0c3349 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0ab9-9041000000-bbc2a82c8786fe62ed22 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-05n3-9043000000-17f7c108d09e594861fd Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 197.9901793 predictedDarkChem Lite v0.1.0 [M-H]- 187.40324 predictedDeepCCS 1.0 (2019) [M+H]+ 198.0526793 predictedDarkChem Lite v0.1.0 [M+H]+ 189.22813 predictedDeepCCS 1.0 (2019) [M+Na]+ 197.9538793 predictedDarkChem Lite v0.1.0 [M+Na]+ 194.83395 predictedDeepCCS 1.0 (2019)
Targets
![](https://go.drugbank.com/assets/locked/DrugTargets2-682eb846d210ae4bf33ca03febccfb57bb1c61318e699b729e5df4dfab2c5b67.png)
- Kind
- Protein
- Organism
- Plasmodium falciparum
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- EXP-1
- Uniprot ID
- P04926
- Uniprot Name
- Malaria protein EXP-1
- Molecular Weight
- 17449.565 Da
References
- Lisewski AM, Quiros JP, Ng CL, Adikesavan AK, Miura K, Putluri N, Eastman RT, Scanfeld D, Regenbogen SJ, Altenhofen L, Llinas M, Sreekumar A, Long C, Fidock DA, Lichtarge O: Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate. Cell. 2014 Aug 14;158(4):916-28. doi: 10.1016/j.cell.2014.07.011. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Glucuronosyltransferase activity
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
- Gene Name
- UGT2B7
- Uniprot ID
- P16662
- Uniprot Name
- UDP-glucuronosyltransferase 2B7
- Molecular Weight
- 60694.12 Da
References
- Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, Thu le TA, Hung NC, Pirmohamed M, Park BK, Edwards G: Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos. 2002 Sep;30(9):1005-12. doi: 10.1124/dmd.30.9.1005. [Article]
- FDA Approved Drug Products: Artesunate Intravenous Injection [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Retinoic acid binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
- Gene Name
- UGT1A9
- Uniprot ID
- O60656
- Uniprot Name
- UDP-glucuronosyltransferase 1-9
- Molecular Weight
- 59940.495 Da
References
- Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, Thu le TA, Hung NC, Pirmohamed M, Park BK, Edwards G: Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos. 2002 Sep;30(9):1005-12. doi: 10.1124/dmd.30.9.1005. [Article]
- FDA Approved Drug Products: Artesunate Intravenous Injection [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
- Gene Name
- CYP2A6
- Uniprot ID
- P11509
- Uniprot Name
- Cytochrome P450 2A6
- Molecular Weight
- 56501.005 Da
References
- Phompradit P, Muhamad P, Cheoymang A, Na-Bangchang K: Preliminary investigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria. Am J Trop Med Hyg. 2014 Aug;91(2):361-6. doi: 10.4269/ajtmh.13-0531. Epub 2014 Jun 2. [Article]
- Artesunate Product Information [Link]
- Artesunate and Amiodiquine FDA Label [File]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Veerappan A, Eichhorn T, Zeino M, Efferth T, Schneider D: Differential interactions of the broad spectrum drugs artemisinin, dihydroartemisinin and artesunate with serum albumin. Phytomedicine. 2013 Aug 15;20(11):969-74. doi: 10.1016/j.phymed.2013.04.003. Epub 2013 May 16. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
- Gene Name
- ABCG2
- Uniprot ID
- Q9UNQ0
- Uniprot Name
- ATP-binding cassette sub-family G member 2
- Molecular Weight
- 72313.47 Da
References
- FDA Approved Drug Products: Artesunate Intravenous Injection [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- FDA Approved Drug Products: Artesunate Intravenous Injection [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
- Gene Name
- SLCO1B1
- Uniprot ID
- Q9Y6L6
- Uniprot Name
- Solute carrier organic anion transporter family member 1B1
- Molecular Weight
- 76447.99 Da
References
- FDA Approved Drug Products: Artesunate Intravenous Injection [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
- Gene Name
- SLC22A8
- Uniprot ID
- Q8TCC7
- Uniprot Name
- Solute carrier family 22 member 8
- Molecular Weight
- 59855.585 Da
References
- FDA Approved Drug Products: Artesunate Intravenous Injection [Link]
Drug created at October 28, 2015 21:21 / Updated at February 02, 2024 22:52